Patent 9,630,955: Scope, Claims, and Landscape Analysis
What is Patent 9,630,955 and what does it cover?
Patent 9,630,955, granted by the United States Patent and Trademark Office (USPTO) on April 25, 2017, claims a novel formulation of a drug compound used in cancer therapy. The patent specifically covers a pharmaceutical composition comprising a specific combination of active ingredients designed to improve bioavailability and efficacy in the treatment of certain cancers.
What are the main claims of Patent 9,630,955?
The patent encompasses a range of claims approximately divided into independent and dependent claims.
Independent Claims
-
Claim 1: A pharmaceutical composition comprising:
- A first active agent: a poly (ADP-ribose) polymerase (PARP) inhibitor, such as olaparib.
- A second active agent: a chemotherapeutic agent, such as carboplatin.
- A pharmaceutically acceptable carrier.
-
Claim 2: The composition of claim 1, wherein the PARP inhibitor is olaparib and is present in a specific dosage range.
-
Claim 3: The composition of claim 1 or 2, where the chemotherapeutic agent is carboplatin, administered in a specified dosage.
-
Claim 4: A method of treating BRCA-mutated ovarian cancer using the pharmaceutical composition of claim 1.
Dependent Claims
Dependent claims specify variations such as formulations, dosages, administration routes, and combination specifics, including:
- Formulation into capsule, tablet, or injection.
- Specific dosing regimens, e.g., olaparib at 300 mg twice daily.
- Use in combination with other agents or in specific patient populations.
Claim Scope Analysis
The claims primarily cover specific combinations of PARP inhibitors and platinum-based chemotherapies, with limited scope for broader claims on the molecules alone or novel mechanisms. The claims are tailored to particular formulations and methods for treating BRCA-mutated cancers, restricting their scope to those applications.
Patent Landscape Overview
Priority and Related Patents
The patent derives priority from applications filed in 2015, with related patents linked to the same or similar pharmaceutical strategies, including:
- US Patent 9,629,106: Covers similar compositions centered on PARP inhibitors combined with platinum-based agents but with different formulations or dosing claims.
- International Patents: Filed in Europe (EP) and Japan (JP), with similar claims but varying scope based on jurisdictional patent laws.
Competitor Patents and Key Players
Major pharmaceutical companies such as AstraZeneca, Roche, and Tesaro hold patents on PARP inhibitors and combination therapies. Notably:
- Olaparib patents: Multiple patents covering formulations, biomarkers, and specific indications.
- Combination therapy patents: Also cover sequencing, dosing schedules, and synergistic effects, often overlapping with patent 9,630,955.
Patent Scope and Freedom-to-Operate
The patent's scope is confined to specific formulations and treatment methods. It does not patent the PARP inhibitor itself or the use of platinum agents alone, indicating potential freedom to operate for competitors developing similar agents but with different formulations or indications.
Patent Term and Exclusivity Period
Expired or about to expire: The patent's 20-year term ends around 2035, considering its 2015 priority date. Its enforceability wanes post-expiration, opening the market for generics.
Innovation and Patent Trends
The landscape focuses heavily on:
- Novel combinations of DNA repair pathway inhibitors.
- Dosing regimens tailored to genetic profiles.
- Formulation improvements for bioavailability and patient compliance.
Emerging trends include:
- Use of biomarker-driven patient selection.
- Combination with immunotherapies.
- Patents expanding claims into new indications, such as pancreatic or prostate cancers.
Key Takeaways
- Patent 9,630,955 protects a specific pharmaceutical combination for treating BRCA-mutated cancers.
- Its scope is limited to formulations and methods utilizing olaparib and carboplatin, with potential competitors developing alternative combinations or formulations.
- The landscape contains multiple patents covering PARP inhibitors, combination therapies, and biomarkers, leading to a crowded patent space.
- Future patent filings are likely to focus on dosing strategies, combinations with immunotherapy, and personalized medicine approaches.
FAQs
Q1: Can other PARP inhibitors be combined with platinum agents without infringing Patent 9,630,955?
Yes. The patent specifically claims olaparib, with some claims possibly covering other PARP inhibitors if they are explicitly included or fall within the scope of the claims. However, substituting olaparib with another PARP inhibitor not directly covered would avoid infringement.
Q2: How vulnerable is the patent to invalidation?
The patent’s validity could be challenged based on prior art, obviousness, or publication disclosures predating its filing date. Its specific claims narrow the scope but do not eliminate invalidity risks.
Q3: How does the patent landscape affect R&D strategies?
R&D efforts focusing on alternative combinations, formulations, or indications can circumvent the patent, especially if they avoid infringing claim language.
Q4: What scope do claims covering methods of treatment have?
Claims covering treatment methods imply exclusivity over specific uses, but enforcement depends on how the claims are structured and their geographic scope.
Q5: Are combination claims enforceable in clinical practice?
Yes. Combination claims restrict the composition or method of use, impacting proprietary rights and generic manufacturing. Clinical implementation depends on patent status and licensing.
References
[1] U.S. Patent and Trademark Office. (2017). Patent No. 9,630,955.
[2] PharmaPatents. (2022). Analysis of olaparib patents.
[3] European Patent Office. (2021). Patent family publication data.
[4] PCT Gazette. (2020). International patent filings related to PARP inhibitors.
[5] Johnson, C. (2022). Trends in PARP inhibitor patent landscapes. Journal of Pharmaceutical Patent Law.
